CD28 and breast carcinoma: To evaluate in vitro anti-tumor effects based on the anti-PD-L1 mAb in the 4T1 mouse mammary carcinoma model, we measured the proliferation of CD8+ T cells after anti-CD3/CD28 antibody stimulation.